Soleno Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Soleno Therapeutics, a clinical-stage biopharmaceutical firm, announced CEO Anish Bhatnagar will present a corporate overview at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation will be available on-demand starting May 24 at 7 AM ET on the company’s website. Soleno focuses on developing therapeutics for rare diseases, with its lead candidate, DCCR, a treatment for Prader-Willi syndrome, currently in Phase 3 clinical trials.

REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Investment Conference, being held May 23-26, 2022, virtually and in Miami, FL.

The presentation will be available on-demand beginning at 7 AM Eastern Time on Tuesday, May 24, 2022 in the Investors section on the Company’s website at www.soleno.life.

About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in an ongoing Phase 3 clinical development program. For more information, please visit www.soleno.life.

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578

FAQ

When is Soleno Therapeutics presenting at the H.C. Wainwright Global Investment Conference?

Soleno Therapeutics will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022.

Where can I watch the Soleno Therapeutics presentation?

The presentation by Soleno Therapeutics will be available on-demand on their website starting May 24, 2022, at 7 AM ET.

What is DCCR, the lead candidate from Soleno Therapeutics?

DCCR is a once-daily oral tablet being developed by Soleno Therapeutics for the treatment of Prader-Willi syndrome.

What is the current status of DCCR's clinical trials?

DCCR is currently undergoing evaluation in an ongoing Phase 3 clinical development program.

Who is the CEO of Soleno Therapeutics?

Anish Bhatnagar is the Chief Executive Officer of Soleno Therapeutics.

What is the stock symbol for Soleno Therapeutics?

The stock symbol for Soleno Therapeutics is SLNO.